Our new review article, just published in Cellular and Molecular Biology Letters, discusses recent and exciting advances in the development of hypoimmunogenic islets for diabetes cell therapy.
We explore two major strategies:
- Hypoimmunogenic pluripotent stem cell–derived islets
- Hypoimmunogenic cadaveric islets
Both approaches aim to overcome one of the greatest challenges in islet transplantation — immune rejection — by leveraging cutting-edge gene-editing technologies to create immune-evasive cells. These advances hold great promise for the development of “off-the-shelf” cell therapies that could one day eliminate the need for long-term immunosuppression in patients with diabetes.
The review also highlights:
- Key breakthroughs in genome engineering of PSCs and cadaveric islets
- Clinical progress, including the first patient trial using hypoimmune cadaveric islets
- Current challenges and safety considerations for effective clinical translation
Read the full article here: https://rdcu.be/eJxKo